CYP2A6 and neoplasm: In addition, by stratifying the TCGA dataset between patients with disrupted TP53 (mutation or loss) and those with WT TP53, we further determined that high expression of CYP2A6 and retention of WT TP53 coincided with increased survival compared with all other combinations of tumours harbouring low expression of CYP2A6 and/or loss of WT TP53 (Fig. 4G).